Investment Highlights

The global market for Oxygen-18 (O-18), a rare and stable isotope target for making the PET isotope Flourine-18 (F-18), is approx. $38M and has been growing almost 20% annually. The market for PET-specific isotopes is currently over $1B, growing over 25% annually, providing a great opportunity for AMIC to position itself as a major supplier of O-18 to other major F-18 FDG manufacturers.
Technology advances in medical isotope manufacturing allow AMIC to site, build and operate the LINAC isotope production centers at significantly lower costs than traditional cyclotron accelerators, affording AMIC substantial cost reductions and enables AMIC to generate a broader product line.
AMIC purchased the first Linear Accelerator (LINAC) located in North America specifically designed for the purpose of PET isotopes production, with expanded capability to produce other high demand isotopes.
AMIC completed the standard PET facility design, the LINAC production facility and the dispensing laboratory, and delivers F-18 FDG to regional customers.
AMIC ships stable isotopes to customers worldwide.
AMIC has licensed the intellectual property rights for an advanced neutron production device.
AMIC is developing a proprietary production method to manfacture Molybdenum 99 (Mo-99) - a method which the Company believes will be the fastest and least expensive with highest yeild to solve the current critical shortage of Mo-99.
AMIC is devoping new breakthroughs in brachytherapy (implanted nuclear medicine agents for treatment of many solid tumor cancers) ultizing resorbable Yttrium-90 (Y-90) seeds.
Comprised of top industry experts for isotope production and application, AMIC offers a highly experienced management team to move the company forward.